莱茵生物停牌筹划控制权变更 交易对手方拟注入关联资产

Group 1 - The company announced a suspension of trading due to a planned change in control and the issuance of shares to acquire assets [1] - The controlling shareholder, Qin Benjun, is negotiating to transfer part of his shares and relinquish voting rights, with agreements signed with major counterparties [1][2] - The transaction will result in Beijing Jinkangpu becoming a subsidiary of the company, included in the consolidated financial statements, and is expected to be an affiliated transaction [2] Group 2 - Guangzhou Defu Nutrition, the acquiring party, was established on December 2, 2025, and has a capital contribution of 1.35 billion yuan, with a significant majority from Guangzhou Defu Investment Management [2] - Beijing Jinkangpu, the target of the acquisition, specializes in food nutrition fortifiers and has been operational since 2004, serving various sectors including infant food and health supplements [2] - The company focuses on the production and operation of natural health products, with expertise in over 300 standardized plant extraction technologies and a range of products including monk fruit and stevia extracts [3] Group 3 - In the first three quarters of the year, the company reported revenue of 1.272 billion yuan, an increase of 8.73%, while net profit attributable to shareholders decreased by 30.73% to 70.3953 million yuan [3] - The transaction is expected to enhance the company's capabilities in product formulation and core competitiveness in the food and health supplement sectors, leveraging synergies between the two entities [3] - The collaboration aims to ensure a supply of natural raw materials and enhance global marketing capabilities, fostering a mutually beneficial development model [3]